Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Ligand to Acquire Pfenex Inc.
CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application
Ligand Reports Second Quarter 2020 Financial Results
Ligand’s Second Quarter Financial Results to be Reported August 3rd
Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets
Ligand CEO Issues Letter to Captisol Customers
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
Ligand Reports First Quarter 2020 Financial Results
Ligand’s First Quarter Financial Results to be Reported May 6th
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
